Burn Wound Infections - RECCE® 327 Topical
Aggressive infection is the leading cause of death and morbidity of burn wound sufferers. The most relevant and dangerous of burn wound infections are those involving Staphylococcus aureus (S. aureus), a Gram-positive bacteria located on the skin and mucous membranes (most often the nasal area).
S. aureus is the most dangerous of all of the many common staphylococcal bacteria. This bacteria often causes skin infections; however, it can also cause pneumonia, bone infections, meningitis and other invasive infections.
With the emergence of multi-drug resistant strains such as Methicillin-resistant Staphylococcus aureus (MRSA or ‘golden staph’), effective treatment options are often lacking. Patients with MRSA have significantly longer hospital stays and are estimated to be 64% more likely to die than people with a non-resistant form of the infection.
Burn Wound Infection Cases and Fatalities by Geographical Area
- 11 million cases requiring medical intervention annually
- 300,000 deaths annually
- European Burn Care market calculated at 530 million annually in 2020
- expected to grow to 710 million by end of 2025
- 500,000 burn wound injuries requiring medical intervention annually
- Approximately 50,000 burn-related hospital admissions annually
About RECCE® 327 Topical
RECCE® 327 (R327) as a topical formulation is being studied for efficacy on a broad range of bacterial wounds, burns and skin infections.
A preclinical topical burn study in rats showed significant antibacterial activity against MRSA: Data demonstrated reduced bacterial load and higher percentage of wound closure with increasing doses of R327 compared to Soframycin. A separate human skin model showed the antibiotic was non-irritating, even at high concentrations.
Ongoing Clinical Trials
Recce has begun a Phase I/II clinical trial to assess the potential of R327’s new spray-on, broad-spectrum antibiotic for the treatment of topical burn wound infections.
The study will enroll up to 30 patients and be conducted at Fiona Stanley Hospital Burns Unit in Perth Western Australia. The study will assess the safety and efficacy of R327 as a broad-spectrum spray-on antibiotic for patients with Gram-positive and Gram-negative bacterial burn wound infections, potentially expanding to a comparative effectiveness study based on the data.
More information on this trial can be found at the Australia New Zealand Clinical Trials Registry under the trial ID ACTRN12621000412831 – Proof of concept study of RECCE 327 topical antibiotic therapy for infected burn wounds in adults
|Asset Route of administration||Indications||Discovery||Preclinical||Phase I||Phase II||Phase III||Next data readout||Market Size|
|R327 Topical||Wound infections including infected burns||
||Phase I/II readout Q4 2021||11 million burn wound cases requiring medical intervention. Majority of which escalate to infection|